CEL-SCI announces new LEAPS data presented at i-Chem2019
CEL-SCI announced new LEAPS data presented at i-Chem2019. The LEAPS work was performed in conjunction with researchers at CEL-SCI on CEL-4000 and a newly discovered LEAPS conjugate, DerG-PG275Cit. Both vaccines were evaluated alone and in combination in the model of proteoglycan, or PG, induced arthritis, or PGIA, called recombinant PG G1 domain-induced arthritis, or GIA, an autoimmune mouse model of rheumatoid arthritis, or RA. The conclusion was that vaccination with DerG LEAPS conjugates of distinct PG epitopes alone or together were effective at modulating the inflammatory response and arresting the progression of arthritis. As observed previously, the DerGPG70 conjugate modulated disease through up-regulation of Th2, and down-regulation of Th1 and Th17 responses. The results suggest that the two vaccines act mechanistically on different immune responses. The combination of the two vaccines provided not only broader epitope coverage, but also a greater therapeutic effect than either vaccine alone. The LEAPS platform technology is currently being utilized to develop a therapeutic antigen-specific treatment for RA under a $1.5M grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, or NIAMS, part of the National Institutes of Health, or NIH. Upon completion of preclinical and investigational new drug, or IND, enabling studies for the antigen-specific LEAPS vaccine treatment of RA, CEL-SCI intends to file an IND application with the FDA.